Sema4: A Patient-Centered Health Intelligence Company

Advancing Healthcare

through information-
driven insights

A Health Intelligence Company That Puts Patients in the Center

Sema4 is founded on the idea that more information, deeper analysis, and increased engagement will improve the diagnosis, treatment, and prevention of disease.

Learn more

Centrellis™

Our unique analytics platform, Centrellis, allows us to offer advanced tools to help providers better manage data for patient populations, launch new clinical studies, and easily compare patient outcomes across a healthcare system.

Learn more

Women’s Health

From pregnancy planning to expanded carrier screening, we deploy robust science and cutting-edge tools to give patients more actionable information all along the family journey through advanced genomic testing.

Learn more

Precision Oncology

Our family of precision oncology products and services, Sema4 Signal™, provides data-driven care solutions with advanced analytics, digital tools, and exome-based somatic and hereditary cancer genomic tests.

Learn more

Biopharma

Sema4 offers an extensive portfolio of health information solutions, including pre-clinical and clinical trial support, analytics for actionable insights, and advanced sequencing services, to drive informed decision-making across the drug discovery, development, and commercialization lifecycle.

Learn more

Robust Research

Sema4’s internationally recognized research is run by world leaders in data science, network modeling, multiscale biotechnology, and genomics. We’ve published more than 1,000 peer-reviewed publications in the last five years and remain committed to making new biological discoveries.

Learn more

Latest News

June 17th, 2021

Sema4 Appoints Andrew Kasarskis, Health Data Expert and Precision Medicine Scientist, as Chief Data Officer

Andrew Kasarskis, PhD, has joined Sema4 in the newly established role of Chief Data Officer. Dr. Kasarskis brings more than 20 years of leadership and broad experience.

June 10th, 2021

Sema4 and CM Life Sciences Announce the Filing of Amended Preliminary Proxy Statement

Sema4 and CM Life Sciences (Nasdaq: CMLF), a special purpose acquisition company, filed the amended proxy statement related to their proposed business combination. Sema4 also announced its financial results for the first quarter of 2021.

May 25th, 2021

AdventHealth and Sema4 Launch a Data-driven Precision Medicine Program

AdventHealth and Sema4 have announced a wide-ranging collaboration that will provide new research insights and offer genomic solutions across 20+ hospitals and emergency departments.

Featured In

Awards and Recognition